তেজৰ কেন্সাৰ (AML লিউকেমিয়া)
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
ক’ত যাব
এই ট্ৰায়েলৰ বাবে ভাৰতৰ ১১খন হস্পিতালত ৰোগী লোৱা হৈছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing d…
স্পন্সৰ: AbbVie
ClinicalTrials.gov-ত NCT07044687
ৰেজিস্ট্ৰীত শেষ আপডেট 11 ছেপ্টেম্বৰ 2026 · আমি পঢ়িছোঁ 20 অক্টোবৰ 2026